Connect Biopharma snags $115 million in Series C to develop arsenal of immune modulators
Zheng Wei and William Pan met in a molecular biology study group in college in Guangzhou, China.
In the following decades, the duo transformed from college note-takers to co-founders of Taicang, China-based Connect Biopharmaceuticals. And on Monday, they completed a $115 million Series C to propel their pipeline of immune modulators.
“The amount and the type of investors that we have in this round — it really is a big boost for the company,” said Wei, who most recently served as director of immunology at San Diego-based Arena Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.